A nice start to the week as the market held it’s ground but ended the markets winning streak. The futures are red at the moment but not down too much. Seems all the dips are supported the last few weeks so not concerned about any pullbacks, as they are short lived. Quite a few earnings yesterday and this morning. VMW, BMC, STX all bombed and are down big, F beat but is down on europe concerns. HOG, LLY, and PFE beat and look good pre-market.
The plan today is to stick with yesterdays winners, as well as possibly adding some $SODA calls for a bounce. I will be watching $AMZN like a hawk, but will be hard pressed to buy any calls as they are so expensive. I have a feeling it will overshoot over $300, but the $310 weekly calls are 1.55!!!!! If the plan changes I will post in chat and twitter today.
CMG had price increase from BAC this morning, so continue to like for a $320+ break. LNKD moved nicely and will likely hold my entire position into tomorrow, where I will look to close some out before the close and FB earnings.
SHLD surprised me as I thought we had a few days to get in, and I really like her for next week. I was able to get some Feb 16th 52.50 calls @ .30 an they closed at .84. If not in, its possible you could overpay only to watch it pull back a bit, so be a bit careful for now.
Here are the analyst changes i like this morning:
Chipotle investor sentiment more positive, says BofA/Merrill
BofA/Merrill said Chipotle's pre-announcement a few weeks ago clarified near-term issues and has shifted sentiment positively, allowing investors to focus on long-term fundamentals. The firm expects long-term unit growth and metrics, new businesses, and aggressive buybacks to drive shares. The firm rates Chipotle a Buy with an increased price target of $350, up from $310.
Keryx Biopharmaceuticals price target raised to $11 from $3 at Oppenheimer
Oppenheimer increased its target on Keryx after the company reported stronger than expected data for its Phase III trial evaluating Zerenex for the treatment of hyperphosphatemia in dialysis patients. The firm believes that Zerenex is very attractive from a commercial perspective, and it reiterates an Outperform rating on the stock.
Seagate investment validates Fusion-io market opportunity, says Piper Jaffray
Piper Jaffray views Seagate's (STX) $40M investment in Virident as a validation of the overall market opportunity for Fusion-io (FIO). The firm says Virident is the only logical alternative to Fusion-io and that Seagate's investment likely increases the takeover premium Fusion-io will garner. Piper thinks Seagate's investment will not change the competitive dynamic in the space as Virident has already received investments from Intel (INTC), Cisco (CSCO), Micron (MU) and others. The firm keeps an Overweight rating on Fusion-io shares with a $33 price target.
Salesforce.com initiated with a Buy at Maxim
I will be sticking to the same holdings from yesterday which are SHLD 52.50 FEB calls - CMG 330/335 weekly calls - LNKD 130/135 weekly calls
Here are the strikes I am looking to add this morning on SODA :
|Stock Ticker||Call/Put||Strike||Expiration||Closing Price||Entry Price|
I am still in a lot of positions to include BPT, SAM, SBUX, TZOO, and KERX.
LeeMalone will be doing another class on using Think or Swim and trading options. The class will be for gold members and above at 4:30 on Thursday. Registration link will be up later today!
Lets have a great day!!